SBI Investment Portfolio Company Novorex Takes on Parkinson’s, an ‘Incurable Disease,’ with AI Drug Discovery Technology… Featured in The Chosun Ilbo’s ‘Startup Insight’

• Son Woo-sung, CEO of Novorex, an SBI Investment portfolio company developing small-molecule drugs using AI, was featured in an interview in The Chosun Ilbo's ‘Startup Insight,’ which highlighted the company's distinctive drug discovery methodology combining the speed of AI with biophysical validation.
• Novorex is developing ‘NRX-NGT002,’ a drug candidate targeting LRRK2, a key protein implicated in Parkinson's disease, as its lead pipeline, and has raised a cumulative KRW 44.6 billion from investors including SBI Investment.
• Accelerating development with the goal of submitting an Investigational New Drug (IND) application for a global Phase 1 trial within the year, the company is drawing attention as a K-bio innovation that could open a new path to treating Parkinson's, long considered incurable.

The full article is available at the link below.

https://n.news.naver.com/mnews/article/023/0003987918?sid=101